ArticleJournal of the American Heart Association2024
Cardiovascular Risk Estimation Is Suboptimal in People With HIV.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characterization and risk stratification of coronary artery disease in people living with HIV: a global systematic review.Frontiers in cardiovascular medicine · 2025Pooled it
- Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.Circulation · 2025Trial
- Gender Differences in Statin Discontinuation and Adherence Among Privately Insured People with HIV in the USA.Journal of general internal medicine · 2026 · on this mapObservational
- Extreme Cardiovascular Risk and LDL-C Target Achievement in People With HIV.Open forum infectious diseases · 2026Article
- Evolving paradigms in the management of dyslipidemia: comparison between the 2019 ESC/EAS guidelines and the 2025 focus update.Internal and emergency medicine · 2026Review
- Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program.HIV medicine · 2026Article
- Major adverse cardiovascular events, morbidity, and mortality, among people living with and without HIV in two northern Uganda hospitals.BMC infectious diseases · 2026Article
- The Emerging Role of Interleukin-32 in HIV-Associated Cardiovascular Comorbidities: A Mini Review.International journal of general medicine · 2026Review
- People living with HIV on modern antiretrovirals do not display a pro-atherogenic lipid profile and have similar body composition compared to healthy controls.HIV medicine · 2026Article
- Prediction of Cardiovascular Risk Among People with HIV Using the PREVENT Equations Compared to the Pooled Cohort Equations.Journal of general internal medicine · 2026Observational
- Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis - 2025.Arquivos brasileiros de cardiologia · 2025Article
- HIV: is it now a thing of the past?Internal medicine journal · 2025Review
- Predicting Risk of Cardiovascular Disease Events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort.AIDS (London, England) · 2025Article
- Cardiovascular Risk in People Living with HIV: A Preliminary Case Study from Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Balancing polypharmacy and comorbidity management: cardiovascular health.Current opinion in HIV and AIDS · 2025Review
- Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study.Open forum infectious diseases · 2025Article
- Challenges of HIV Management in an Aging Population.Current HIV/AIDS reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundEstablished cardiovascular disease (CVD) risk prediction functions may not accurately predict CVD risk in people with HIV. We assessed the performance of 3 CVD risk prediction functions in 2 HIV cohorts. METHODS AND
resultsCVD risk scores were calculated in the Mass General Brigham and Kaiser Permanente Northern California HIV cohorts, using the American College of Cardiology/American Heart Association atherosclerotic CVD function, the FHS (Framingham Heart Study) hard coronary heart disease function and the Framingham Heart Study hard CVD function. Outcomes were myocardial infarction or coronary death for FHS hard coronary heart disease function; and myocardial infarction, stroke, or coronary death for American College of Cardiology/American Heart Association and FHS hard CVD function. We calculated regression coefficients and assessed discrimination and calibration by sex; predicted to observed risk of outcome was also compared. In the combined cohort of 9412, 158 (1.7%) had a coronary heart disease event, and 309 (3.3%) had a CVD event. Among women, CVD risk was generally underestimated by all 3 risk functions. Among men, CVD risk was underestimated by the American College of Cardiology/American Heart Association and FHS hard CVD function, but overestimated by the FHS hard coronary heart disease function. Calibration was poor for women using the FHS hard CVD function and for men using all functions. Discrimination in all functions was good for women (c-statistics ranging from 0.78 to 0.90) and moderate for men (c-statistics ranging from 0.71 to 0.72).
conclusionsEstablished CVD risk prediction functions generally underestimate risk in people with HIV. Differences in model performance by sex underscore the need for both HIV-specific and sex-specific functions. Development of CVD risk prediction models tailored to HIV will enhance care for aging people with HIV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.